» Articles » PMID: 36203054

Microglial Hexokinase 2 Deficiency Increases ATP Generation Through Lipid Metabolism Leading to β-amyloid Clearance

Abstract

Microglial cells consume adenosine triphosphate (ATP) during phagocytosis to clear neurotoxic β-amyloid in Alzheimer's disease (AD). However, the contribution of energy metabolism to microglial function in AD remains unclear. Here, we demonstrate that hexokinase 2 (HK2) is elevated in microglia from an AD mouse model (5xFAD) and AD patients. Genetic deletion or pharmacological inhibition of HK2 significantly promotes microglial phagocytosis, lowers the amyloid plaque burden and attenuates cognitive impairment in male AD mice. Notably, the ATP level is dramatically increased in HK2-deficient or inactive microglia, which can be attributed to a marked upregulation in lipoprotein lipase (LPL) expression and subsequent increase in lipid metabolism. We further show that two downstream metabolites of HK2, glucose-6-phosphate and fructose-6-phosphate, can reverse HK2-deficiency-induced upregulation of LPL, thus supporting ATP production and microglial phagocytosis. Our findings uncover a crucial role for HK2 in phagocytosis through regulation of microglial energy metabolism, suggesting a potential therapeutic strategy for AD by targeting HK2.

Citing Articles

Do microglia metabolize fructose in Alzheimer's disease?.

Sturno A, Hassell Jr J, Lanaspa M, Bruce K J Neuroinflammation. 2025; 22(1):85.

PMID: 40089786 DOI: 10.1186/s12974-025-03401-x.


Drofenine as a Kv2.1 inhibitor alleviated AD-like pathology in mice through A/Kv2.1/microglial NLRP3/neuronal Tau axis.

Lu J, Zhou Q, Zhu D, Song H, Xie G, Zhao X Acta Pharm Sin B. 2025; 15(1):371-391.

PMID: 40041886 PMC: 11873626. DOI: 10.1016/j.apsb.2024.11.010.


Phagocytic Function Analyses of GABR-Related Microglia in Immature Developing Epileptic Brain Based on 10× Single-Nucleus RNA Sequencing Technology.

Gan Y, Yang X, Li T, Han Z, Cheng L, Xie L Biomedicines. 2025; 13(2).

PMID: 40002683 PMC: 11853619. DOI: 10.3390/biomedicines13020269.


Glucose Metabolic Reprogramming in Microglia: Implications for Neurodegenerative Diseases and Targeted Therapy.

Fang M, Zhou Y, He K, Lu Y, Tao F, Huang H Mol Neurobiol. 2025; .

PMID: 39987285 DOI: 10.1007/s12035-025-04775-y.


Lactylation in cancer: metabolic mechanism and therapeutic strategies.

Sui Y, Shen Z, Wang Z, Feng J, Zhou G Cell Death Discov. 2025; 11(1):68.

PMID: 39979245 PMC: 11842571. DOI: 10.1038/s41420-025-02349-4.


References
1.
Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

2.
Guo T, Zhang D, Zeng Y, Huang T, Xu H, Zhao Y . Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. Mol Neurodegener. 2020; 15(1):40. PMC: 7364557. DOI: 10.1186/s13024-020-00391-7. View

3.
Chen Z, Zhong C . Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol. 2013; 108:21-43. DOI: 10.1016/j.pneurobio.2013.06.004. View

4.
Butterfield D, Halliwell B . Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019; 20(3):148-160. PMC: 9382875. DOI: 10.1038/s41583-019-0132-6. View

5.
Wang W, Zhao F, Ma X, Perry G, Zhu X . Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: recent advances. Mol Neurodegener. 2020; 15(1):30. PMC: 7257174. DOI: 10.1186/s13024-020-00376-6. View